Milestone Pharmaceuticals Price to Free Cash Flow Ratio 2018-2024 | MIST

Milestone Pharmaceuticals price to free cash flow ratio from 2018 to 2024. Price to free cash flow ratio can be defined as

Milestone Pharmaceuticals Price to Free Cash Flow Ratio 2018-2024 | MIST

Milestone Pharmaceuticals price to free cash flow ratio from 2018 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$173B
Vertex Pharmaceuticals (VRTX)$127.1B
Gilead Sciences (GILD)$114.2B
Bristol Myers Squibb (BMY)$112.1B
CSL (CSLLY)$91B
Regeneron Pharmaceuticals (REGN)$89.7B
GSK (GSK)$74.4B
Argenex SE (ARGX)$35.2B
Alnylam Pharmaceuticals (ALNY)$35.2B
Biogen (BIIB)$25.4B
BioNTech SE (BNTX)$25.4B
Illumina (ILMN)$24.2B
Moderna (MRNA)$19.9B
BeiGene (BGNE)$19.7B
Incyte (INCY)$15.6B
Genmab (GMAB)$14.8B
Insmed (INSM)$13B
Vaxcyte (PCVX)$13B
BioMarin Pharmaceutical (BMRN)$12.6B
Sarepta Therapeutics (SRPT)$12.2B
Bio-Techne Corp (TECH)$12B
Exelixis (EXEL)$10.1B
Exact Sciences (EXAS)$10.1B
QIAGEN (QGEN)$10B
Revolution Medicines (RVMD)$9.9B
Intra-Cellular Therapies (ITCI)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$8.7B
Repligen (RGEN)$8.2B
Ascendis Pharma (ASND)$7.8B